# Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin

> **NCT00207402** · PHASE4 · COMPLETED · sponsor: **Brooke Army Medical Center** · enrollment: 34 (actual)

## Conditions studied

- Hepatitis C

## Interventions

- **DRUG:** rosiglitazone

## Key facts

- **NCT ID:** NCT00207402
- **Lead sponsor:** Brooke Army Medical Center
- **Sponsor class:** FED
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-10
- **Primary completion:** 2010-01
- **Final completion:** 2010-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2012-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00207402

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00207402, "Infergen, Ribavirin & Avandia in Previous Relapsers or Nonresponders to Pegylated Interferon and Ribavirin". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00207402. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*